tbuckley/cabot-search huggingface dataset:
Predictive Role of <i>CD36</i> Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab
Authors: Francesca Ligorio, Serena Di Cosimo, Paolo Verderio, Chiara Maura Ciniselli, Sara Pizzamiglio, Lorenzo Castagnoli, Matteo Dugo, Barbara Galbardi, Roberto Salgado, Sherene Loi, Stefan Michiels, Tiziana Triulzi, Elda Tagliabue, Sarra El-Abed, Miguel Izquierdo, Evandro de Azambuja, Paolo Nuciforo, Jens Huober, Luca Moscetti, Wolfgang Janni, Maria Antonia Coccia-Portugal, Paola Antonia Corsetto, Antonino Belfiore, Daniele Lorenzini, Maria Grazia Daidone, Andrea Vingiani, Luca Gianni, Serenella Maria Pupa, Giampaolo Bianchini, Giancarlo Pruneri, Claudio Vernieri
Journal: JNCI Journal of the National Cancer Institute (2022)

Abstract Background Despite huge efforts to identify biomarkers associated with long-term clinical outcomes in patients with early-stage HER2-positive breast cancer (HER2+ BC) treated with (neo)adjuvant anti-HER2 therapy, no reliable predictors have been identified so far. Fatty acid uptake, a process mediated by the transmembrane transporter CD36, has recently emerged as a potential determinant of resistance to anti-HER2 treatments in preclinical HER2+ BC models. Methods Here, we investigated the association between baseline intratumor CD36 gene expression and event-free survival in 180 patients enrolled in the phase III trial Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO), which randomly assigned stage II-III HER2+ BC patients to receive neoadjuvant lapatinib, trastuzumab, or lapatinib-trastuzumab in combination with chemotherapy. To this aim, we selected NeoALTTO trial patients for whom pretreatment whole transcriptomic data were available. The main study results were validated in an independent cohort of patients enrolled in the neoadjuvant phase II trial NeoSphere. Results In 180 NeoALTTO patients, high intratumor CD36 expression was independently associated with worse event-free survival in patients treated with trastuzumab-based therapy (hazard ratio [HR] = 1.72, 95% confidence interval [CI] = 1.20 to 2.46), but not with lapatinib-based (HR = 1.02, 95% CI = 0.68 to 1.53) or trastuzumab-lapatinib–based (HR = 1.08, 95% CI = 0.60 to 1.94) therapy. Among 331 NeoSphere patients evaluated, high CD36 expression was independently associated with worse patient disease-free survival in both the whole study cohort (HR = 1.197, 95% CI = 1.002 to 1.428) and patients receiving trastuzumab-based neoadjuvant therapy (HR = 1.282, 95% CI = 1.049 to 1.568). Conclusions High CD36 expression predicts worse clinical outcomes in early-stage HER2+ BC treated with trastuzumab-based neoadjuvant therapy.
Sex-dependent hepatoprotective role of IL-22 in NAFLD-related fibrosis
Authors: Mohamed Noureldin Hassan Ali Abdelanbi, Manuel Flores Molina, Geneviève Soucy, Vincent Quoc-Huy Trinh, Nathalie Bédard, Sabrina Mazouz, Jessica Dion, Sarah Tran, Marc Bilodeau, Naglaa Shoukry
Journal: Journal of Hepatology (2022)
Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study
Authors: Madhumita Shrotri, Maria Krutikov, Hadjer Nacer-Laidi, Borscha Azmi, Tom Palmer, Rebecca Giddings, Christopher Fuller, Aidan Irwin-Singer, Verity Baynton, Gokhan Tut, Paul Moss, Andrew Hayward, Andrew Copas, Laura Shallcross
Journal: The Lancet Healthy Longevity (2022)

Residents and staff in long-term care facilities have been prioritised for vaccination against SARS-CoV-2, but data on potential waning of vaccine effectiveness and the effect of booster doses in this vulnerable population are scarce. We aimed to evaluate effectiveness of one, two, and three vaccine doses against infection and severe clinical outcomes in staff and residents of long-term care facilities in England over the first year following vaccine roll-out.
Development and validation of a novel ICP-MS method to quantify different copper species in human plasma from patients with Wilson disease
Authors: Tao Liang, Haiting Zhang, Linwen Zhang, Scott Moseley, Ping Guo, Meng Chen, Tracey Hall, Ming Li, Eugene Swenson, Wei-Jian Pan, Brian Meltzer, Ryan Pelto, Mark Ma
Journal: Journal of Hepatology (2022)
Safety, tolerability and pharmacokinetics of single ascending doses of ALG-020572, a GalNAc-conjugated antisense oligonucleotide, in healthy subjects
Authors: Edward J Gane, Man-Fung Yuen, Christian Schwabe, Min Wu, Kha Le, Jen Rito, Kusum Gupta, Christopher Westland, Felix Lai, Meenakshi Venkatraman, Megan Fitzgerald, Tse-I Lin, Lawrence Blatt, Sushmita Chanda, Matt McClure, John Fry, Kosh Agarwal
Journal: Journal of Hepatology (2022)
Identification of new dominant neoantigens in hepatocellular carcinoma based on a single plasmid system with co-expressing patient’s HLA and antigen
Authors: Pu Chen, Dongbo Chen, Shaoping She, Yao Yang, Liying Ren, Bigeng Zhao, Ruifeng Yang, Weijia Liao, Hongsong Chen
Journal: Journal of Hepatology (2022)
Greater sequence diversity during early hepatitis B virus decline on vebicorvir plus entecavir is associated with a lower level of virus rebound following switch to entecavir monotherapy
Authors: Lewyn Li, Peter Revill, Ran Yan, Calvin Chan, Hua Tian, Julie Ma, Luisa M Stamm, Man-Fung Yuen, Alexander Thompson, Kathryn M Kitrinos
Journal: Journal of Hepatology (2022)
Spontaneous and drug-induced histological changes in non-alcoholic steatohepatitis: an assessment by meta-analysis of trials
Authors: Grazia Pennisi, Ciro Celsa, Marco Enea, Marco Vaccaro, Vito Di Marco, Carlo Ciccioli, Giuseppe Infantino, Stefanie Parisi, Claudia La Mantia, Antonio Craxi, Calogero Camma, Salvatore Petta
Journal: Journal of Hepatology (2022)
Different acylcarnitines tissue profiles as metabolomics signatures of human hepatocellular carcinoma in non-alcoholic fatty liver disease according to fibrosis level
Authors: Benjamin Buchard, Natali Abeywickrama Samarakoon, Estelle Pujos-Guillot, Stéphanie Durand, Mélanie Petera, Delphine Centeno, Juliette Joubert, Aicha Demidem, Armand Abergel
Journal: Journal of Hepatology (2022)
The proteomic analysis of hepatic stellate cell differentiation from iPSCs identifies RORalpha as an antifibrogenic target
Authors: Raquel A Martinez Garcia de la Torre, Julia Vallverdu, Sylvia Arino Mons, Beatriz Aguilar-Bravo, Mikel Azkargorta, Felix Elortza, laura Zanatto, Paula Cantallops Vilà, Juanjo Lozano, Benedicte Antoine, Isabel Graupera, Pere Ginès, Pau Sancho-Bru
Journal: Journal of Hepatology (2022)
IMC-I109V, a novel T cell receptor (TCR) bispecific (ENVxCD3) designed to eliminate HBV-infected hepatocytes in chronic HBV patients: initial data from a first-in-human study
Authors: Stefan Bourgeois, Young-Suk Lim, Edward J Gane, Hyun Woong Lee, Wendy Cheng, Jeong Heo, Won Kim, Maria Buti, Alexander Thompson, Gail Matthews, Ewa Janczewska, Stephen Ryder, Raul J. Andrade, Yuan Yuan, Adel Benlahrech, Jay Wustner, Lucy Dorrell, Man-Fung Yuen
Journal: Journal of Hepatology (2022)
Magnesium modulation by CNNM4 silencing in DIAMOND mice via GalNAc-siRNA therapy: a new and effective therapeutic approach against MAFLD
Authors: Rubén Rodríguez Agudo, Naroa Goikoetxea, Miren Bravo, Sofia Lachiondo-Ortega, Marina Serrano-Macia, Maria Mercado-Gómez, Marcos Fernandez Fondevila, Teresa Cardoso Delgado, Luis Alfonso Martinez-Cruz, Franz Martin-Bermudo, Ruben Nogueiras, Cesar Augusto Martín, Ute Schaeper, Daniela Buccella, Jorge Simón, María Luz Martínez-Chantar
Journal: Journal of Hepatology (2022)
Incidence and predictors of hepatocellular carcinoma development in patients with autoimmune hepatitis: a multicenter international study
Authors: Francesca Colapietro, Patrick Maisonneuve, Ellina Lytvyak, Ulrich Beuers, Robert Verdonk, Adriaan Van der Meer, Bart Van Hoek, Sjoerd Kuiken, Hans Brouwer, Egbert-Jan van der Wouden, Alessio Aghemo, Aad van den Berg, George Dalekos, Mercedes Robles-Díaz, Raul J. Andrade, Aldo J. Montano-Loza, Floris F. van den Brand, Guilherme Macedo, Rodrigo Liberal, Ynto de Boer, Ana Lleo
Journal: Journal of Hepatology (2022)
In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy
Authors: Romina Salpini, Stefano D’Anna, Mohammad Alkhatib, Lorenzo Piermatteo, Alessandro Tavelli, Eugenia Quiros-Roldan, Antonella Cingolani, Chiara Papalini, Stefania Carrara, Massimo Puoti, Loredana Sarmati, Antonella d’Arminio Monforte, Francesca Ceccherini Silberstein, Carlo Federico Perno, Valentina Svicher
Journal: Journal of Hepatology (2022)
Proximity labelling reveals potential cis interactions of CD52 glycoprotein counter-receptors on circulating CD4+HLA-G+ regulatory T cells in acute decompensation of cirrhosis
Authors: Tong Liu, Gang Wu, Cathrin Gudd, Thomas Barbera, Rooshi Nathwani, Francesca Trovato, Yan Liu, Mark J W McPhail, Mark Thursz, Wafa Khamri
Journal: Journal of Hepatology (2022)
Long-chain acylcarnitines promote leukocyte mitochondrial dysfunction: role in patients with acutely decompensated cirrhosis
Authors: Ingrid Wei Zhang, Cristina López-Vicario, Mireia Casulleras, Marta Duran-Güell, Roger Flores-Costa, Paula Segalés, M.Carme Garcia-Ruiz, José Fernandez-Checa, Joan Clària
Journal: Journal of Hepatology (2022)
Combination of CCL4-induced decompensated cirrhosis with acute polymicrobial peritonitis as an optimized experimental model mimicking extrahepatic organ failures defined in ACLF
Authors: Roger Flores-Costa, Albert Salvatella, Bryan J Contreras, Marta Duran-Güell, Mireia Casulleras, Nico Kraus, Sabine Klein, Cristina López-Vicario, Ingrid Wei Zhang, Pierre-Emmanuel Rautou, Javier Fernández, Jonel Trebicka, Vicente Arroyo, Joan Clària
Journal: Journal of Hepatology (2022)
Machine learning models for prediction of severe portal hypertension in patients with compensated cirrhosis
Authors: Oleksandr Petrenko, Jiří Reiniš, Benedikt Simbrunner, Benedikt Hofer, Pierre-Emmanuel Rautou, Lucile Moga, Jonel Trebicka, Wenyi Gu, Philip Georg Ferstl, Lise Lotte Gluud, Flemming Bendtsen, Søren Møller, Agustin Albillos, Luis Téllez, Sven Francque, Wilhelmus Kwanten, Juan Carlos Garcia Pagan, Valeria Perez, Virginia Hernandez-Gea, Filippo Schepis, Marco Scoppettuolo, Dario Saltini, Càndid Villanueva, Anna Brujats, Mattias Mandorfer, Thomas Reiberger
Journal: Journal of Hepatology (2022)
Non-alcoholic fatty liver disease patients have worse health-related quality of life compared to the general population irrespective of their fibrosis stage: results from a prospective multicenter UK study
Authors: Margarita Papatheodoridi, Giada Pallini, Guruprasad Aithal, Hong Kai Lim, Jeremy Cobbold, Maria Corina Plaz Torres, Marta Guerrero Misas, John Ryan, Jeremy Tomlinson, Michael Allison, Louise Longworth, Emmanuel Tsochatzis
Journal: Journal of Hepatology (2022)
Novel strategies required to further improve outcomes in acute liver failure
Authors: William Bernal, Mark J.W McPhail, Anshuman Singh, Brian J. Hogan, Tasneem Pirani, Sameer Patel, Robert Loveridge, Christopher Willars, Michael Heneghan, Varuna Aluvihare, Parthi Srinivasan, Andreas Prachalias, Georg Auzinger, Nigel Heaton, Julia Wendon
Journal: Journal of Hepatology (2022)
Predictive factors of tumor recurrence after liver transplantation for hepatocellular carcinoma: analysis of a multicenter prospective study including 371 patients
Authors: Thomas Decaens, René Adam, Sébastien Dharancy, Laurent Sulpice, Didier Samuel, Emmanuel Boleslawski, Marianne Latournerie, Georges-Philippe Pageaux, Olivier Scatton, Sylvie Radenne, Eric Savier, Claire Francoz, Claire Vanlemmens, Pierre-Henri Bernard, Jean Hardwigsen, Jean Gugenheim, Christophe Duvoux, Nadia Oubaya
Journal: Journal of Hepatology (2022)
Postprandial dysfunction in metabolic associated fatty liver disease (MAFLD)
Authors: Josephine Grandt, Anne Sofie Jensen, Mikkel Werge, Elias Rashu, Anders Junker, Lise Hobolth, Christian Mortensen, Maria Kristiansen, Mogens Vyberg, Reza Serizawa, Søren Møller, Lise Lotte Gluud, Nicolai J. Wewer Albrechtsen
Journal: Journal of Hepatology (2022)
The discriminatory power of risk scores for hepatocellular carcinoma in treated chronic hepatitis B patients with and without diabetes: a territory-wide study of 48,706 subjects
Authors: Terry Cheuk-Fung Yip, Mandy Sze-Man Lai, Vincent Wai-Sun Wong, Yee-Kit Tse, Yan Liang, Vicki Wing-Ki Hui, Henry LY Chan, Grace Lai-Hung Wong
Journal: Journal of Hepatology (2022)
Knockdown of Glyoxylate reductase/hydroxypyruvate reductase (GRHPR) accelerates liver regeneration and decreases chronic liver damage
Authors: Viktoriia Iakovleva, Anna Potapova, Agnes Bee, Leng Ong, Rong Gao, Yock Young Dan, Torsten Wuestefeld
Journal: Journal of Hepatology (2022)
Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks
Authors: Maria Buti, Heiner Wedemeyer, Soo Aleman, Vladimir Chulanov, Morozov Viacheslav, Olga Sagalova, Tatyana Stepanova, Robert G. Gish, Andrew Lloyd, Ankita Kaushik, Vithika Suri, Dmitry Manuilov, Anu Osinusi, John F. Flaherty, Pietro Lampertico
Journal: Journal of Hepatology (2022)
Hepatocyte-derived biomarkers concentrations predict liver-related events within 2 years in patients with Child-Pugh class A alcohol-related cirrhosis
Authors: Laure Elkrief, Nathalie Ganne-Carrié, Hana Manceau, Marion Tanguy, Nathalie Barget, Cendrine Chaffaut, Shantha Valainathan, Alix Riescher, Katell Peoch, Thierry Poynard, Sylvie Chevret, Pierre-Emmanuel Rautou
Journal: Journal of Hepatology (2022)
Improving NIAAA criteria for the diagnosis of alcoholic hepatitis, role of systemic inflammation
Authors: Elisa Pose, Emma Avitabile, Alba Díaz, Carla Montironi, Martina Perez, Jordi Gratacós-Gines, Helena Hernandéz Evole, Tejasav Sehrawat, Harmeet Malhi, Pol Olivas, Virginia Hernandez-Gea, Vijay Shah, Patrick S. Kamath, Pere Ginès
Journal: Journal of Hepatology (2022)
Bulevirtide avoids future clinical events and related costs compared to pegylated-interferon alpha in chronic hepatitis D in Spain
Authors: Maria Buti, José Luis Calleja Panero, Miguel Ángel Rodríguez Sagrado, Helena Cantero, Ana de las Heras, Raquel Domínguez-Hernández, Miguel Ángel Casado
Journal: Journal of Hepatology (2022)
Comparison of hepatic and cardiovascular damage between HIV patients with steatosis and NAFLD: role of metabolic alterations and low visceral adiposity
Authors: Felice Cinque, Rosa Lombardi, Annalisa Cespiati, Paolo Francione, Erika Fatta, Cristina Bertelli, Giuseppina Pisano, Giovanna Oberti, Lucia Colavolpe, Francesca Alletto, Paola Dongiovanni, Marica Meroni, Giorgio Bozzi, Alessandra Bandera, Anna Ludovica Fracanzani
Journal: Journal of Hepatology (2022)
Germline genetic risk factors for the development of hepatocellular carcinoma among patients with cirrhosis: a genome-wide association study of U.S. veterans
Authors: David Kaplan, Marijana Vujkovic, Daniel Dochterman, Kirk Wangensteen, Poornima Devineni, Tae-Hwi Linus Schwantes-An, Anoop Sendamarai, Purushtotham Karnam, Emily Sileo, Tori Anglin, Trina Norden-Krichmar, Philip Tsao, Timothy Morgan, Saiju Pyarajan, Julie Lynch, Benjamin Voight, Kyong-Mi Chang
Journal: Journal of Hepatology (2022)
Association of long term methotrexate therapy with liver fibrosis markers: a multi-centre prospective case-control study
Authors: Edmond Atallah, Jane Grove, Colin Crooks, Esther Burden-teh, Ruth Murphy, Sulleman Moreea, Abhishek Abhishek, Kelsey Jordan, Aftab Ala, David Hutchinson, Richard Aspinall, Guruprasad Aithal
Journal: Journal of Hepatology (2022)
Quantifying Individual-Level Inaccuracy in Glomerular Filtration Rate Estimation
Authors: Tariq Shafi, Xiaoqian Zhu, Seth T. Lirette, Andrew D. Rule, Thomas Mosley, Kenneth R. Butler, Michael E. Hall, Pradeep Vaitla, James J. Wynn, Maria Clarissa Tio, Neville R. Dossabhoy, Eliseo Guallar, Javed Butler
Journal: Annals of Internal Medicine (2022)

Although the population-level differences between estimated glomerular filtration rate (eGFR) and measured glomerular filtration rate (mGFR) are well recognized, the magnitude and potential clinical implications of individual-level differences are unknown.To quantify the magnitude and consequences of the individual-level differences between mGFRs and eGFRs.Cross-sectional study.Four U.S. community-based epidemiologic cohort studies with mGFR.3223 participants in 4 studies.The GFRs were measured using urinary iothalamate and plasma iohexol clearance; the eGFR was calculated from serum creatinine concentration alone (eGFRCR) and with cystatin C. All GFR results are presented as mL/min/1.73 m2.The participants' mean age was 59 years; 32% were Black, 55% were women, and the mean mGFR was 68. The population-level differences between mGFR and eGFRCR were small; the median difference (mGFR - eGFR) was -0.6 (95% CI, -1.2 to -0.2); however, the individual-level differences were large. At an eGFRCR of 60, 50% of mGFRs ranged from 52 to 67, 80% from 45 to 76, and 95% from 36 to 87. At an eGFRCR of 30, 50% of mGFRs ranged from 27 to 38, 80% from 23 to 44, and 95% from 17 to 54. Substantial disagreement in chronic kidney disease staging by mGFR and eGFRCR was present. Among those with eGFRCR of 45 to 59, 36% had mGFR greater than 60 whereas 20% had mGFR less than 45; among those with eGFRCR of 15 to 29, 30% had mGFR greater than 30 and 5% had mGFR less than 15. The eGFR based on cystatin C did not provide substantial improvement.Single measurement of mGFR and serum markers without short-term replicates.A substantial individual-level discrepancy exists between the mGFR and the eGFR. Laboratories reporting eGFR should consider including the extent of this uncertainty to avoid misinterpretation of eGFR as an mGFR replacement.National Institutes of Health.
Durability of SARS-CoV-2 specific immune response following different primary prime-boost vaccine platforms and subsequent humoral response to booster dose among liver transplant recipients
Authors: Supachaya Sriphoosanaphan, Sirinporn Suksawatamnuay, Nunthiya Srisoonthorn, Nipaporn Siripon, Panarat Thaimai, Wanwisar Makhasen, Nawakodchamon Mungnamtrakul, Kessarin Thanapirom, Bunthoon Nonthasoot, Pokrath Hansasuta, Piyawat Komolmit
Journal: Journal of Hepatology (2022)
Ascites bacterial DNA and IL-6 are promising tools in the diagnosis of spontaneous bacterial peritonitis
Authors: Arno Hagenunger, Niklas F Aehling, Adam Herber, Rhea Veelken, Sandra Krohn, Katharina Zeller, Kathrin Jaeger, Daniel Seehofer, Sebastian Rademacher, Robert Sucher, Cornelius Engelmann, Thomas Berg
Journal: Journal of Hepatology (2022)
Aldafermin quantitatively improves inflammation in a 24-week clinical trial in patients with nonalcoholic steatohepatitis
Authors: Tian Lan, Luong Ruiz, Wenhui Liu, Amir Ashique, Harry Chen, Jiping Zha, Alex DePaoli, Igor Mikaelian, Cynthia Guy, Eugenia Henry, Corinne Foo-Atkins, William Chang, Hsiao Lieu
Journal: Journal of Hepatology (2022)
FMO2 (Flavin Containing Monooxygenase 2) Prevents Cardiac Fibrosis via CYP2J3-SMURF2 Axis
Authors: Cheng Ni, Yongjian Chen, Yinchuan Xu, Jing Zhao, Qingju Li, Changchen Xiao, Yan Wu, Jingyi Wang, Yingchao Wang, Zhiwei Zhong, Ling Zhang, Rongrong Wu, Qingnian Liu, Xianpeng Wu, Changle Ke, Wei Zhu, Jinghai Chen, Jijun Huang, Yibin Wang, Jian’an Wang, Xinyang Hu
Journal: Circulation Research (2022)

Background: Cardiac fibrosis is a common pathological feature associated with adverse clinical outcome in postinjury remodeling and has no effective therapy. Using an unbiased transcriptome analysis, we identified FMO2 (flavin-containing monooxygenase 2) as a top-ranked gene dynamically expressed following myocardial infarction (MI) in hearts across different species including rodents, nonhuman primates, and human. However, the functional role of FMO2 in cardiac remodeling is largely unknown. Methods: Single-nuclei transcriptome analysis was performed to identify FMO2 after MI; FMO2 ablation rats were generated both in genetic level using the CRISPR-cas9 (clustered regularly interspaced short palindromic repeats/clustered regularly interspaced short palindromic repeat–associated 9) technology and lentivirus-mediated manner. Gain-of-function experiments were conducted using postn -promoter FMO2, miR1a/miR133a-FMO2 lentivirus, and enzymatic activity mutant FMO2 lentivirus after MI. Results: A significant downregulation of FMO2 was consistently observed in hearts after MI in rodents, nonhuman primates, and patients. Single-nuclei transcriptome analysis showed cardiac expression of FMO2 was enriched in fibroblasts rather than myocytes. Elevated spontaneous tissue fibrosis was observed in the FMO2-null animals without external stress. In contrast, fibroblast-specific expression of FMO2 markedly reduced cardiac fibrosis following MI in rodents and nonhuman primates associated with diminished SMAD2/3 (small mothers against decapentaplegic 2/3) phosphorylation. Unexpectedly, the FMO2-mediated regulation in fibrosis and SMAD2/3 signaling was independent of its enzymatic activity. Rather, FMO2 was detected to interact with CYP2J3 (cytochrome p450 superfamily 2J3). Binding of FMO2 to CYP2J3 disrupted CYP2J3 interaction with SMURF2 (SMAD-specific E3 ubiquitin ligase 2) in cytosol, leading to increased cytoplasm to nuclear translocation of SMURF2 and consequent inhibition of SMAD2/3 signaling. Conclusions: Loss of FMO2 is a conserved molecular signature in postinjury hearts. FMO2 possesses a previously uncharacterized enzyme-independent antifibrosis activity via the CYP2J3-SMURF2 axis. Restoring FMO2 expression exerts potent ameliorative effect against fibrotic remodeling in postinjury hearts from rodents to nonhuman primates. Therefore, FMO2 is a potential therapeutic target for treating cardiac fibrosis following injury.
Bile duct on a chip: engineering a microfluidic platform for studying biliary epithelium in a dish
Authors: Jorke Willemse, Mees N.S. de Graaf, Gilles van Tienderen, Luc J.W. van der Laan, Valeria Orlova, Jeroen de Jonge, Monique M.A. Verstegen
Journal: Journal of Hepatology (2022)
Peroxiredoxin 2 is a target for hepatocellular carcinoma chemoprevention
Authors: Emilie Crouchet, Eugénie Schaeffer, Hussein El Saghire, Naoto Fujiwara, Frank Jühling, Marine Oudot, Clara Ponsolles, Nicolas Brignon, Sarah Durand, Marie Parnot, Danijela Heide, Jenny Hetzer, Mathias Heikenwälder, Emanuele Felli, Patrick Pessaux, Nathalie Pochet, Yujin Hoshida, Laurent Mailly, Thomas Baumert, Catherine Schuster
Journal: Journal of Hepatology (2022)